EUVIMEDEUVIMED entdecken
Übersichtsarbeit

CD25 : A potential tumor therapeutic target

Yujia Peng, Yiran Tao iD, Ya Zhang, Jiaxing Wang, Jinliang Yang, Yuxi Wang

International Journal of Cancer · 2023-04 · 152 (7) · 1290-1303

DOI: 10.1002/ijc.34281 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift International Journal of Cancer, 2022-10. Verfasst von Yujia Peng und 5 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Biotherapy, Targeted Tracer Research and Development Laboratory, Institute of Respiratory Health, Frontiers Science Center fo…. Hauptthemen laut MEDLINE: T-Lymphocytes, Regulatory, Neoplasms. Die Arbeit wurde bisher 107-mal zitiert (Crossref) und nennt 111 Literaturangaben. Gefördert von: National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

CD25 is the alpha‐chain of the heterotrimer IL‐2 receptor. CD25 is expressed on the surface of both immune and non‐immune cells with different frequencies. For cancers, CD25 is expressed at high levels in many types of hematological malignancies, but at low levels in most solid tumors. CD25 is also highly expressed in activated circulating immune cells and regulatory T cells (Tregs). Infiltration of Tregs in the tumor microenvironment can lead to an imbalanced ratio of effector T cells (Teffs) and Tregs, which is associated with the progression of cancers. A rescued Teff/Treg cell ratio indicates an efficient anti‐tumor response to immunotherapy. CD25 as a potential target for the depletion of Tregs is critical in developing new immunotherapeutic strategies. Few articles have summarized the relationships between CD25 and tumors, or the recent progress of drugs targeting CD25. In this paper, we will discuss the structures of IL‐2 and IL‐2R, the biological function of CD25 and its important role in tumor therapy. In addition, the latest research on drugs targeting CD25 has been summarized, providing guidance for future drug development.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

T-Lymphocytes, RegulatoryNeoplasmsHumansInterleukin-2 Receptor alpha SubunitImmunotherapyTumor Microenvironment

Stichwörter der Autor:innen

CD25anti-CD25 drugsregulatory T cellstumor immunotherapy

Substanzen

Interleukin-2 Receptor alpha Subunit

Autor:innen und Institutionen

  • State Key Laboratory of Biotherapy, Targeted Tracer Research and Development Laboratory, Institute of Respiratory Health, Frontiers Science Center for Disease- related Molecular Network, National Clinical Research Cente…
  • West China-California Research Center for Predictive Intervention Medicine, West China Hospital, Sichuan University, Chengdu, Sichuan, China.
  • Precision Medicine Key Laboratory of Sichuan Province & Precision Medicine Research Center, West China Hospital, Sichuan University, Chengdu, Sichuan, China.
  • College of Life Sciences, Sichuan University, Chengdu, Sichuan, China.
  • Department of Pharmaceutical Sciences, College of Pharmacy, University of Tennessee Health Science Center, Memphis, Tennessee, USA.

ORCID-Profile: Yiran Tao

Förderung

  • National Natural Science Foundation of China

Zitieren

APA

Peng, Y., Tao, Y., Zhang, Y., Wang, J., Yang, J., & Wang, Y. (2023). CD25 : A potential tumor therapeutic target. International Journal of Cancer, 152(7), 1290-1303. https://doi.org/10.1002/ijc.34281

Vancouver

Peng Y, Tao Y, Zhang Y, Wang J, Yang J, Wang Y. CD25 : A potential tumor therapeutic target. International Journal of Cancer. 2023;152(7):1290-1303. doi:10.1002/ijc.34281

BibTeX
@article{Peng2023,
  author = {Peng, Yujia and Tao, Yiran and Zhang, Ya and Wang, Jiaxing and Yang, Jinliang and Wang, Yuxi},
  title = {CD25 : A potential tumor therapeutic target},
  journal = {International Journal of Cancer},
  year = {2023},
  volume = {152},
  number = {7},
  pages = {1290--1303},
  doi = {10.1002/ijc.34281}
}
Kostenlos starten →